International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Kumar, Shaji; Paiva, Bruno; Anderson, Kenneth C.; Durie, Brian G.M.; Landgren, Ola; Moreau, Philippe; Munshi, Nikhil C.; Lonial, Sagar; Bladé, Joan; Mateos, María Victoria; Dimopoulos, Meletios Α.; Boccadoro, Mario; Orłowski, Robert Z.; Goldschmidt, Hartmut; Spencer, Andrew; Hou, Jian; Chng, Wee Joo; Usmani, Saad Z.; Zamagni, Elena; Shimizu, Kazuyuki; Jagannath, Sundar; Johnsen, Hans Erik; Terpos, Evangelos; Reiman, Anthony; Kyle, Robert A.; Sonneveld, Pieter; Richardson, Paul G.; McCarthy, Philip L.; Ludwig, Heinz; Chen, Wen-Ming; Cavo, Michèle; Harousseau, Jean Luc; Lentzsch, Suzanne; Hillengaß, Jens; Palumbo, Antônio; Órfão, Alberto; Rajkumar, S. Vincent; Miguel, Jesús F. San; Avet-Loiseau, Hervé

doi:10.1016/s1470-2045(16)30206-6

Cited by 2,152 publications

(2,028 citation statements)

References 118 publications

Supporting

Mentioning

1,830

Contrasting

Unclassified

Order By: Relevance

“…After therapy completion, each patient's response to the treatment was evaluated according to the International Myeloma Working Group criteria. 10 The study protocol conformed to the Ethical Guidelines of the World Medical Association Declaration of Helsinki and was approved by the Bioethical Commission of the Poznan University of Medical Sciences, Poznań, Poland. Progression-free survival (PFS) and OS were analyzed using the PRISM software version 5.0 (GraphPad Software, La Jolla, California, United States).…”

Section: Patients and Methods Patients And Samplesmentioning

confidence: 99%

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Łuczak¹,

Kubicki²,

Rzetelska³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Section: Patients and Methods Patients And Samplesmentioning

confidence: 99%

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Łuczak¹,

Kubicki²,

Rzetelska³

et al. 2017

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

“…Therefore, survival was analyzed in 187 patients. The IMWG criteria 4,12,13 were used to assess diagnosis and treatment response. Pretreatment MDCT studies were performed as baseline bone surveys in all patients.…”

Section: Study Design and Patientsmentioning

confidence: 99%

Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma

Matsue¹,

Kobayashi²,

Matsue

et al. 2018

Blood Advances

View full text Add to dashboard Cite

Key Points• Bone marrow abnormalities were detected in the AS of 196 consecutive symptomatic patients with MM.• Medullary abnormalities in the AS were associated with a poor prognosis, independent of other clinical parameters.We aimed to determine the clinical and prognostic significance of medullary abnormalities detected by low-dose whole-body multidetector computed tomography ( 1.12-3.31; P 5 .018) were independent predictors of progression-free survival. Age and focal (HR, 2.51; 95% CI, 1.14-5.56; P 5 .023) and diffuse (HR, 4.12; 95% CI, 1.74-9.77; P 5 .001) patterns were also independent predictors of OS. The addition of marrow pattern to preexisting risk factors was associated with a net reclassification improvement for predicting OS (to 0.37, P 5 .015). Medullary abnormalities in the AS (detected by low-dose whole-body MDCT) are associated with a poor prognosis, independent of other clinical variables.

show abstract

“…100 mg/kg melphalan was used for the conditioning regimen. Response was assessed according to the International Myeloma Working Group (IMWG) Response Criteria [7].…”

Section: Methodsmentioning

confidence: 99%

Result of Bortezomib Induction Therapy Prior to Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia

Batsukh,

Norov,

Jigjidkhorloo

et al. 2017

Cent. Asian j. Med. Sci.

View full text Add to dashboard Cite

Objectives:For last 5 years, we have focused on establishing autologous stem cell transplantation (ASCT) in Mongolia. Herein, we report on three Mongolian multiple myeloma (MM) cases treated with bortezomib and dexamethasone (VD) prior to ASCT. Methods: The MM diagnosis was confirmed by bone marrow aspiration, urine protein electrophoresis, and serum protein electrophoresis. Results: Circulating white blood cells appeared 8-10 days after ASCT. Platelet levels recovered 10 -15 days after ASCT. Conclusion: In our MM cases, the VD regimen prior to ASCT obtained good response rates without the impairment of stem cells.

show abstract

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Cited by 2,152 publications

References 118 publications

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma

Result of Bortezomib Induction Therapy Prior to Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia

Contact Info

Product

Resources

About